- Home
- STAA vs HRMY Comparison
STAA vs HRMY Comparison
Compare STAA & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STAA
- HRMY
- Stock Information
- Founded
- STAA 1982
- HRMY 2017
- Country
- STAA United States
- HRMY United States
- Employees
- STAA N/A
- HRMY N/A
- Industry
- STAA Ophthalmic Goods
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- STAA Health Care
- HRMY Health Care
- Exchange
- STAA Nasdaq
- HRMY Nasdaq
- Market Cap
- STAA 1.4B
- HRMY 2.1B
- IPO Year
- STAA N/A
- HRMY 2020
- Fundamental
- Price
- STAA $27.16
- HRMY $32.63
- Analyst Decision
- STAA Hold
- HRMY Strong Buy
- Analyst Count
- STAA 8
- HRMY 9
- Target Price
- STAA $22.50
- HRMY $55.33
- AVG Volume (30 Days)
- STAA 667.8K
- HRMY 711.5K
- Earning Date
- STAA 10-29-2025
- HRMY 10-28-2025
- Dividend Yield
- STAA N/A
- HRMY N/A
- EPS Growth
- STAA N/A
- HRMY 58.41
- EPS
- STAA N/A
- HRMY 3.10
- Revenue
- STAA $224,449,000.00
- HRMY $772,527,000.00
- Revenue This Year
- STAA N/A
- HRMY $20.09
- Revenue Next Year
- STAA $27.24
- HRMY $16.86
- P/E Ratio
- STAA N/A
- HRMY $10.55
- Revenue Growth
- STAA N/A
- HRMY 17.74
- 52 Week Low
- STAA $13.50
- HRMY $26.47
- 52 Week High
- STAA $38.60
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- STAA 56.68
- HRMY 34.85
- Support Level
- STAA $26.98
- HRMY $31.61
- Resistance Level
- STAA $28.13
- HRMY $32.84
- Average True Range (ATR)
- STAA 0.47
- HRMY 1.16
- MACD
- STAA -0.35
- HRMY -0.47
- Stochastic Oscillator
- STAA 12.86
- HRMY 15.70
About STAA STAAR Surgical Company
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.